Previous 10 | Next 10 |
Idera Pharmaceuticals (NASDAQ: IDRA ) will collaborate with AbbVie (NYSE: ABBV ) on a three-arm Phase 1b open-label clinical trial evaluating combinations of an OX40 agonist (ABBV-368), a TLR-9 agonist (tilsotolimod), chemotherapy (nab-paclitaxel) and/or an anti-programmed cell death 1 (PD...
EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company. The purpose of the collaboration is...
EXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wednesday, September 4, 2019 at 8:30 a.m. Eastern Time at the InterContinental New York Barclay Hotel. ...
Idera Pharmaceuticals, Inc. (IDRA) Q2 2019 Earnings Conference Call August 08, 2019, 10:00 ET Company Participants Vincent Milano - President, CEO & Director Bryant Lim - SVP, General Counsel & Corporate Secretary Elizabeth Tarka - SVP & Chief Medical Officer John K...
Idera Pharmaceuticals (NASDAQ: IDRA ): Q2 GAAP EPS of -$0.39 beats by $0.03 . More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
EXTON, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drug candidates for both oncology and rare disease i...
EXTON, Pa., July 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion of John J. Kirby to Chief Financial Officer. Dr. Tarka was most recently the Vice President of...
EXTON, Pa., June 18, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 2019 JMP Securities Life Sciences Conference on Thursday, June 20, 2019 at 1:30 p.m. Eastern Time at the St. Regis Hotel in New York City. A...
Gainers : Regional Health Properties (NYSEMKT: RHE ) +54% . Zix (NASDAQ: ZIXI ) +34% . Wesco Aircraft (NYSE: WAIR ) +28% . AAC Holdings (NYSE: AAC ) +25% . Maxar Technologies (NYSE: MAXR ) +23% . Idera Pharmaceuticals (NASDAQ: IDRA ) +22% . Mercer International (NASDAQ: M...
Idera Pharmaceuticals (NASDAQ: IDRA ): Q1 GAAP EPS of -$0.40 beats by $0.07 . More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Idera Pharmaceuticals Inc. Company Name:
IDRA Stock Symbol:
NASDAQ Market:
Idera Pharmaceuticals Inc. Website:
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results fo...
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) ...